You are about to go to a non-NYULMC website.
All data from NYU Health Sciences Library Faculty Bibliography — -
Contact:
http://hsl.med.nyu.edu/faculty-bibliography-search [9]
Romiplostim's effect to optimize SVR with telapravir, ribavirin, and PEG interferon-alfa 2a in thrombocytopenic cirrhotics with chronic hepatitis C. restraint C- placebo RCT
Basu, P P; Siriki, R; Shah, N J; Farhat, S; Mittimani, K; Atluri, S; Rahaman, M; Brown, Jr R S
2013 April 2013;58:S373-S374, Journal of hepatology
—
id: 349452,
year: 2013,
vol: 58,
page: S373,
stat: Journal Article,
Telaprevir with adjusted dose of ribavirin in naive CHC-G1: Efficacy and treatment in CHC in hemodialysis population. Target C (RCT)
Basu, P P; Siriki, R; Shah, N J; Farhat, S; Mittimani, K; Atluri, S; Rahaman, M; Brown, Jr R S
2013 April 2013;58:S30-S31, Journal of hepatology
—
id: 349512,
year: 2013,
vol: 58,
page: S30,
stat: Journal Article,
Effect of N acetylcysteine (NAC) in hypoxia induced liver injury (HILI) - A randomized placebo control clinical trial
Basu, P; Siriki, R; Shah, N J; Farhat, S; Mittimani, K; Atluri, S; Rahaman, M; Brown, Jr R S
2013 April 2013;58:S148-S148, Journal of hepatology
—
id: 349482,
year: 2013,
vol: 58,
page: S148,
stat: Journal